Sarcoma  >>  Lartruvo (olaratumab) 
Welcome,         Profile    Billing    Logout  

5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lartruvo (olaratumab) / Eli Lilly
ANNOUNCE, NCT02451943 / 2015-000134-30: A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma

Active, not recruiting
3
509
Europe, Canada, Japan, US, RoW
Olaratumab, LY3012207, Doxorubicin, Placebo
Eli Lilly and Company
Soft Tissue Sarcoma
12/18
07/24
2018-001124-20: Efficacy of Olaratumab and Re-Treatment with Doxorubicin in anthracycline pretreated, advanced soft tissue sarcoma patients.

Ongoing
2
60
Europe
Dexrazoxan, Doxorubicinhydrochlorid, Concentrate for solution for infusion, Powder for solution for infusion, Lartruvo®, CARDIOXANE®
IKF Klinische Krebsforschung GmbH am Krankenhaus Nordwest, Lilly Deutschland GmbH, Clinigen Healthcare Limited
locally advanced (unresectable) or metastatic soft tissue sarcoma, locally advanced (unresectable) or metastatic soft tissue sarcoma, Diseases [C] - Cancer [C04]
 
 
KEYNOTE-505, NCT03126591: A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma

Completed
1a/1b
38
Europe, US
Olaratumab, LY3012207, Pembrolizumab, MK3475
Eli Lilly and Company, Merck Sharp & Dohme LLC
Soft Tissue Sarcoma
05/21
02/23
OLATRASTS, NCT03985722: Olaratumab Plus Trabectedin in Advanced Soft-tissue Sarcoma Patients Soft-tissue Sarcoma Patients

Active, not recruiting
1
28
Europe
Olaratumab and Trabectedin, Lartruvo and Yondelis
Grupo Espanol de Investigacion en Sarcomas
Sarcoma, Soft Tissue
02/21
05/24
NCT03994627: Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma

Available
N/A
Europe, Canada, US, RoW
Olaratumab, LY3012207
Eli Lilly and Company
Soft Tissue Sarcoma
 
 

Download Options